US92337C1045
© BusinessWire
04.02.2026
VSTM
LISTED
NASDAQ
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced preliminary, unaudited fourth quarter and full year 2025 net product revenues for AVMAPKI™ FAKZYNJA™ CO-PACK, business updates, and 2026 priorities.
"2025 was a transformative year...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards w...
Themefolio
Profiler
Peergroup
© BusinessWire
29.12.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus reso...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
15.12.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of develo...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
25.11.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced underwritten public offering of 8,543,794 shares of its common stock at an offering price to the public of $7.25 per share, and in lieu of comm...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Proposed Public Offering of Common Stock
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Verastem Oncology intends to grant the underwriters a...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at Upcoming Investor Conferences
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in November:
Guggenheim Healthcare Conference 2025: Fireside chat on Tuesday,...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the third quarter ended September 30, 2025.
"Our performance in Q3, which was the first full quarter since our accelerated approva...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouraging preliminary data from the first two dose levels in its ongoing Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, i...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET.
To acc...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and safety data from partner GenFleet Therapeutics’ Phase 1/2 monotherapy study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor (VS-7375 outside of...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
07.10.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 138,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an induce...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at Upcoming Investor Conferences
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September:
Cantor Global Healthcare Conference 2025: Fireside chat on Wedn...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated safety and efficacy data and late-breaking presentation details of partner GenFleet Therapeutics’ Phase 1/2 study in China of GFH375, an oral KRAS G12D (ON/OFF) inhi...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET.
To acc...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for the first-line treatment of patients with KR...
Themefolio
Profiler
Peergroup
© BusinessWire
11.07.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avuto...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 45,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducem...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published online in Nature M...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in VS-7375-101, the U.S. Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in patients w...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreati...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York.
A live w...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the first quarter ended March 31, 2025.
“In the first quarter of 2025, we continued to make progress with our pipeline programs by...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
VSTM
LISTED
NASDAQ
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-muta...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at Upcoming Investor Conferences
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May:
H.C. Wainwright 3rd Annual BioConnect Investor Conference: Fireside ch...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces $75 million Private Placement
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its comm...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation. The Co...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of its common stock to fourteen new employees and the grant of 83,333 restricted stock units to one new employee. The awards were granted pursuant to the...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 to be held on April 25-30 in Chicago, Illinois. These presentations w...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and highlighted recent progress.
“In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptan...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, including an oral presentation of additional analyses from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial evaluating the investigatio...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST.
A live webcast of the fireside...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for its novel clinical pipeline.
"We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company’s...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor. In a...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced a new credit facility for up to $150 million along with an equity investment of $7.5 million with Oberland Capital Management LLC (Oberland Capital). In addition, the Company announce...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employe...
Themefolio
Profiler
Peergroup
© BusinessWire
30.12.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defa...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). No dose-lim...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3rd at 11:15 am EST.
A live webcast of the fireside chat can be accesse...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the third quarter ended September 30, 2024.
“In the third quarter of 2024, we made advancements in our recurrent low-grade serous ovarian cancer program, i...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has completed its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational and potential first-in-class combination of avutometinib, an oral R...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
VSTM
LISTED
NASDAQ
Verastem Oncology to Participate in Upcoming Investor Conferences
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences:
2024 Truist Securities BioPharma Symposium on November 7, 2024
Guggenheim Healthcare Innovation Conference; firesi...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from the Phase 2 RAMP 201 (ENGOTov60/GOG3052) clinical trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the Int...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 109,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the empl...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
VSTM
LISTED
NASDAQ
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT.
A live webcast of the fireside chat can be accessed und...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
VSTM
LISTED
NASDAQ
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the acceptance of a late-breaking abstract of the mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the Interna...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
VSTM
LISTED
NASDAQ
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024.
This press release features multimedia. View the full release he...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
VSTM
LISTED
NASDAQ
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the second quarter ended June 30, 2024.
“We have made tremendous progress in the second quarter as we initiated our rolling NDA submission for avutometini...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
